Table 2

Patients description (Ireland)

Patients at randomisationWeb N=52Control N=48
Gender
 Male, N (%)32 (61.5)20 (41.7)
 Female, N (%)20 (38.5)28 (58.3)
 Total5248
Age at diagnosis, median (range)30 (7–64)34 (8–74)
Age at inclusion, median (range)42 (18–68)48 (19–95)
Disease duration (year), median (range)8 (0–32)8 (0–52)
Patients at baselineWeb N=51Control N=41
Gender
 Male, N (%)31 (60.8)17 (41.5)
 Female, N (%)20 (39.2)24 (58.5)
 Total5141
Age at diagnosis, median (range)29 (7–64)34 (8–57)
Age at inclusion, median (range)41 (18–66)46 (19–65)
Disease duration (years), median (range)8 (0–32)8 (1–52)
Disease extension, N (%)
 Proctitis20 (39.2)21 (51.2)
 Left sided18 (35.5)10 (24.4)
 Pancolitis13 (25.5)10 (24.4)
 SCCAI, median (range)1 (0–9)2 (0–7)
5-ASA treatment systemic, N (%)
 Asacol31 (60.8)20 (48.8)
 Pentasa12 (23.5)7 (17.1)
 Dipentum2 (3.9)1 (2.4)
 Salazopyrin1 (2.0)8 (19.5)
 Mezavant0 (0)1 (2.4)
 None5 (9.8)4 (9.8)
Suppositories, N (%)
 Asacol2 (3.9)2 (4.9)
 Pentasa2 (3.9)4 (9.8)
 Salofalk1 (2.0)0 (0)
 None46 (90.2)35 (85.4)
Enema/foam
 Salofalk4 (7.8)1 (2.4)
 Pentasa0 (0)0 (0)
 Colifoam6 (11.8)6 (14.6)
 Pred-Clysma1 (2.0)1 (2.4)
 None40 (78.4)33 (80.5)
BMI, median (range)25 (19–39)27 (19–41)
 Smoking (%)
 Non-smoker25 (49.0)22 (53.7)
 Active smoker11 (21.6)7 (17.1)
 Ex-smoker15 (29.4)12 (29.3)
Marital status (%)
 Married32 (62.7)26 (63.4)
 Single19 (37.3)15 (36.6)
Education (%)
 Academic9 (17.6)8 (19.5)
 Other education32 (62.7)29 (70.7)
 During education10 (19.6)4 (9.8)
Occupation (%)
 Paid41 (80.4)29 (70.7)
 Unpaid8 (15.7)7 (17.1)
 Support2 (3.9)4 (9.8)
 Pensioner0 (0)1 (2.4)